Latent HIV-1 infection of resting CD4+ T Cells in the humanized Rag2 -/- γ c -/- mouse

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 114-120

  Choudhary, Shailesh K ^a   Archin, Nancie M ^a   Cheema, Manzoor ^a   Dahl, Noelle P ^a   Garcia, J Victor ^a   Margolis, David M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; ENFUVIRTIDE; INTEGRASE INHIBITOR; L 870812; RAG2 PROTEIN; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ARTICLE; BONE MARROW CULTURE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; LATENT VIRUS INFECTION; LYMPH NODE; MEMORY T LYMPHOCYTE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; VIREMIA; VIRUS CARRIER; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, KNOCKOUT; VIRUS LATENCY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; PRIMATES; REPLICATION COMPETENT VIRUSES;

EID: 84863393573     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05590-11     Document Type: Article

References (38)

1. Anderson JA, et al. 2011. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J. Virol. 85:5220-5223.
2. Archin NM, et al. 2008. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22:1131-1135.
3. Archin NM, et al. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25:207-212.
4. Baenziger S, et al. 2006. Disseminated and sustained HIV infection in CD34+cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc. Natl. Acad. Sci. U. S. A. 103:15951-15956.
5. Bailey JR, et al. 2006. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80:6441-6457.
6. Berges BK, Akkina SR, Remling L, Akkina R. 2010. Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology 397:100-103.
7. Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R. 2006. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology 3:76.
8. Bieniasz PD, Cullen BR. 2000. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J. Virol. 74:986-9877.
9. Brooks DG, et al. 2003. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19:413-423.
10. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA. 2001. Generation of HIV latency during thymopoiesis. Nat. Med. 7:459-464.
11. Carter CC, et al. 2011. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 9:223-234.
12. c -/-mouse. J. Virol. 83:8254-8258.
13. Chun TW, et al. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:8869-8873.
14. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. 1998. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. 188:83-91.
15. Chun TW, et al. 2010. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24:2803-2808.
16. Chun TW, et al. 2005. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115:3250-3255.
17. Chun TW, et al. 2008. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis. 197: 714-720.
18. Chun TW, et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193-13197.
19. Dinoso JB, et al. 2009. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 83:9247-9257.
20. Finzi D, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
21. Garber ME, et al. 1998. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12:3512-3527.
22. Hermankova M, et al. 2003. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J. Virol. 77:7383-7392.
23. Lambotte O, et al. 2005. Persistence of replication-competent HIV in the central nervous system despite long-term effective highly active antiretroviral therapy. AIDS 19:217-218.
24. Mariani R, et al. 2000. A block to human immunodeficiency virus type 1 assembly in murine cells. J. Virol. 74:3859-3870.
25. Melkus MW, et al. 2006. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12:1316-1322.
26. Moore RD, Keruly JC, Gebo KA, Lucas GM. 2005. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J. Acquir. Immune Defic. Syndr. 39: 195-198.
27. Nettles RE, et al. 2005. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293:817-829.
28. Palmer S, et al. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884.
29. Pantaleo G, et al. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362: 355-358.
30. Pierson TC, et al. 2002. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J. Virol. 76: 8518-8531.
31. Sango K, et al. 2010. Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice. AIDS Res. Hum. Retroviruses 26:735-746.
32. Shen A, et al. 2003. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J. Virol. 77: 4938-4949.
33. Siliciano JD, et al. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-728.
34. Strain MC, et al. 2005. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191:1410-1418.
35. Traggiai E, et al. 2004. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104-107.
36. Uberla K, et al. 1995. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 92:8210-8214.
37. Zhang J, Scadden DT, Crumpacker CS. 2007. Primitive hematopoietic cells resist HIV-1 infection via p21. J. Clin. Invest. 117:473-481.
38. Zhang L, Kovalev GI, Su L. 2007. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 109:2978-2981.